Request To Download Free Sample of This Strategic Report @- The Global Xerostomia Therapeutics Market is poised for significant growth, with an anticipated reach of over USD 822.14 million by 2026, ...

Ribox Therapeutics Ltd. has obtained IND clearance from the FDA for the company’s circular RNA therapy, RXRG-001.

A dry mouth, or xerostomia, is a common condition that affects up to 10million people in the UK. It is most prevalent among older people and those who have had cancer treatment or need to take a mix ...